Vol 95, No 9 (2023)

Cover Page

Full Issue

Editorial

Creation of registers as one of the mechanisms for improving medical care for patients with chronic heart failure. Problem state

Reitblat O.M., Airapetian A.A., Lazareva N.V., Mezhonov E.M., Sorokin E.V., Prints I.S., Blankova Z.N., Svirida O.N., Ageev F.T., Zhirov I.V., Tereshchenko S.N., Boytsov S.A.

Abstract

The annual mortality of patients with clinically pronounced symptoms of chronic heart failure in the Russian Federation reaches 26–29%, i.e., from 880 to 986 thousand patients with heart failure die in the country in one year, which is comparable to the population of a large city. Providing care for patients with heart failure places a heavy burden on the country's health care system, making a significant contribution to mortality rates, hospitalization rates, including readmissions, which in turn requires considerable costs. The article presents an overview of registry studies that are devoted to assessing the effectiveness of diagnostics, the completeness of examinations, as well as the adequacy of ongoing drug treatment.

Terapevticheskii arkhiv. 2023;95(9):739-745
pages 739-745 views

Original articles

Hemostasis disorders in patients with systemic AL-amyloidosis

Rekhtina I.G., Khyshova V.A., Zozulya N.I., Dvirnyk V.N., Mendeleyeva L.P.

Abstract

Aim. To analyze the frequency and nature of hemorrhagic and thrombotic complications in patients with systemic AL-amyloidosis and compare with laboratory changes in the hemostasis system.

Materials and methods. The prospective study included 40 patients with newly diagnosed AL-amyloidosis. To detect amyloid, all patients underwent bone marrow trephine biopsy and duodenal biopsy, and 28 (70%) patients underwent biopsy of the affected organ. Before the start of therapy, all patients were determined the platelet count, activated partial thromboplastin time, thrombin time, fibrinogen concentration, time of XIIa-dependent fibrinolysis, antithrombin III, D-dimer, activity of blood coagulation factors VIII, X and vWF. The statistical part of the study was carried out using the IBM SPSS Statistics 2017 system software (SPSS, Chicago, IL, USA).

Results. In 20 (50%) patients, hemorrhages on the skin and mucous membranes were diagnosed as vascular purpura. Before the start of therapy, 7 (17.5%) patients had thrombosis, including leg vein thrombosis (5 patients), ischemic stroke (2 patients). There was a direct correlation between thrombotic complications and cutaneous hemorrhagic syndrome (p=0.007). In 15 (75%) cases, cutaneous hemorrhagic syndrome was accompanied by hypercoagulable shifts in the hemostasis system. Of the 20 patients with cutaneous hemorrhagic syndrome, 19 (95%) patients had kidney damage, including 15 patients with nephrotic syndrome. Hematoma type of bleeding, as well as heavy bleeding was not observed, including after a biopsy of the internal organs. According to the totality of hemostasis indicators, hypercoagulation syndrome was more often observed (in 23; 56% of patients). Hypocoagulation was diagnosed only in 2 (5%) patients with liver damage, 16 (39%) patients had normocoagulation.

Conclusion. Cutaneous hemorrhagic syndrome is the most common clinical manifestation of disorders in the hemostasis system in patients with AL-amyloidosis. The relationship of hemorrhages on the skin with nephrotic syndrome has been established, which may indicate a single pathogenetic mechanism. Cutaneous hemorrhagic syndrome is associated with hypercoagulable shifts in hemostasis and a high risk of thrombotic complications.

Terapevticheskii arkhiv. 2023;95(9):746-750
pages 746-750 views

Relationship between the pain severity, use of non-steroidal anti-inflammatory drugs and blood pressure in elective large joint arthroplasty of the lower extremities

Okisheva E.A., Mironova O.I., Berdysheva M.V., Pyatigorets E.S., Krivova N.P., Kurnosova A.A., Elizarov M.P., Smetanin S.M., Lychagin A.V., Fomin V.V.

Abstract

Aim. To evaluate the changes in blood pressure (BP), the severity of pain syndrome and non-steroidal anti-inflammatory drugs (NSAIDs) use patterns in patients hospitalized for elective arthroplasty of large joints of the lower extremities during the postoperative period.

Materials and methods. This study included 374 patients. In all patients, medical history, antihypertensive therapy and history of NSAIDs usage were collected, BP was measured, and the severity of pain was assessed via a 10-point scale before surgery, as well as 1 and 3 months after arthroplasty.

Results. The study included 132 (35.3%) males and 242 (64.7%) females. Among these, 289 (77.3%) patients had hypertension [grade 1 – 35 patients, grade 2 – 136 patients, grade 3 – 118 (25.0%) patients]; 280 (74.9%) patients were taking NSAIDs (121 – daily, 135 – 2–3 times per week). The median pain severity before surgery was 8 points [7; 9], 1 month after surgery – 2 points [1; 4], 3 months after surgery – 1 point [0; 3]. At 1 month after arthroplasty, 23 (7.9%) patients reported a decrease in BP. In 17 (5.9%) patients, correction of previously prescribed antihypertensive therapy with a decrease in drug doses was required. At 1 month after arthroplasty, 256 patients discontinued NSAIDs. The analysis of the relationship between the severity of pain, NSAIDs use and the level of BP revealed a significant effect of pain syndrome (p<0.0001) and the use of NSAIDs (p=0.014).

Conclusion. In the population of patients with elective arthroplasty of large joints of the lower extremities, a significant incidence of hypertension and a high prevalence of NSAIDs use are noted. During the postoperative period, a significant trend towards a decrease in the severity of pain was found, as well as the relationship of pain and NSAIDs with a decrease in BP.

Terapevticheskii arkhiv. 2023;95(9):751-756
pages 751-756 views

Five-year dynamics adrenergic reactivity of erythrocytes after radio-frequency sympathic denervation of renal arteries in patients with resistant arterial hypertension

Rebrova T.Y., Falkovskaya A.Y., Afanasiev S.A., Mordovin V.F., Zyubanova I.V., Muslimova E.F.

Abstract

Aim. To study the initial state of adrenergic reactivity and the five-year dynamics of the beta-adrenergic reactivity index of erythrocyte membranes and the manifestation of the antihypertensive effect of the procedure for radiofrequency destruction of sympathetic structures of the renal artery in patients with resistant arterial hypertension.

Subjects and methods. The analysis included 42 patients with resistant arterial hypertension (RH). The renal denervation (RD) procedure of the kidneys was performed by endovascular bilateral transcatheter radiofrequency ablation of the renal arteries. The study of 24-hour blood pressure monitoring (BPM) and the determination of β-adrenoreactivity of erythrocytes (β-ARM) by changes in the osmoresistance of erythrocyte membranes were performed initially, 1 week, 6 months, 1, 2, 3 and 5 years after RD. Patients retrospectively, at a follow-up period of 6 months after RD, were divided into responders (decrease in blood pressure by 10 or more mm Hg) and non-responders (decrease in blood pressure less than 10 mm Hg).

Results. 6 months after the RD, the number of responders was 28 people (66.7%), after 5 years - 31 people (73.8%). At the time of inclusion in the study, the median β-ARM in the group of non-responders was not significantly higher than in the group of responders. After 6 months after the RD procedure, the β-ARM indicator in the non-responder group was significantly lower than in the responder group (p = 0.043). With further follow-up in the group of responders, an increase in the median β-ARM was noted, which reached significant differences relative to the baseline values in the group at follow-up periods of 1 year (p = 0.036) and 5 years (p = 0.004) after RD. The change in the β-ARM indicator in the non-responder group was wavy in nature, the changes did not reach the significance criteria.

Conclusion. Renal denervation in 73.8% of cases is accompanied by a stable antihypertensive response for 5 years of observation and an increase in β-ARM, which may indicate the implementation of compensatory mechanisms in conditions of increasing activity of the sympathoadrenal system in response to a decrease in blood pressure.

Terapevticheskii arkhiv. 2023;95(9):757-762
pages 757-762 views

Albuminuria as a marker of atherosclerosis burden and a possible predictor of adverse events in patients with polyvascular disease

Shakhmatova O.O., Komarov A.L., Krivosheeva E.N., Dobrovolsky A.B., Titaeva E.V., Amelyushkina V.A., Gomyranova N.V., Panchenko E.P.

Abstract

Background. The role of albuminuria as a marker of the atherosclerosis burden and a predictor of prognosis in patients with polyvascular disease (PD) has been little studied.

Aim. To evaluate the prevalence, association with atherosclerosis burden, and prognostic value of albuminuria in relation to cardiovascular and bleeding complications in patients with PD.

Materials and methods. The data was obtained from the prospective registry REGATA-1 (NCT04347200). Seventy four patients (75.7% males, median age 67 [61–69] years) with PD (CAD and peripheral arterial disease) were enrolled. All patients received aspirin and rivaroxaban 2.5 mg. The albumin-creatinine ratio in a single morning urine sample, estimated glomerular filtration rate (eGFR), and von Willebrand factor levels were determined.

Results. Mild albuminuria (10–29 mg/g) was detected in 45.9% of patients, moderate and severe (≥30 mg/g) – in 29.7%; eGFR<60 ml/min – in 21.7%, chronic kidney disease (CKD) according to the full KDIGO criteria (eGFR and/or albuminuria ≥30 mg/g) – twice as often (39.2%). The frequency of nephroprotective therapy prescription was insufficient. The level of albuminuria did not correlate with von Willebrand factor (endothelial dysfunction marker), but was associated with affecting of 4–5 vascular beds (ROC AUC 0.775; p=0.011). During the follow-up (12 [8–18] months) 3 patients developed MACE, 11 – BARC 2–3 bleedings. Neither albuminuria nor eGFR were predictors of MACE, bleeding, or net clinical benefit. CKD (KDIGO) was also not associated with bleedings. CKD (KDIGO) was independent predictor of MACE (in significant multiple regression model beta – coefficient for CKD was 0.097; p=0.042), however, the small number of end points allows us to speak only of a hypothesis-generating trend. The implementation of CKD (KDIGO) has increased the predictive value of the REACH score.

Conclusion. Albuminuria is highly prevalent in patients with PD. It is a marker of atherosclerosis burden. CKD, diagnosed taking into account the level of albuminuria, can be used in a comprehensive assessment of cardiovascular risk in this category of patients.

Terapevticheskii arkhiv. 2023;95(9):763-768
pages 763-768 views

Possibilities of instrumental determination of volemic status in patients with acute decompensation of chronic heart failure

Syrkhaeva A.A., Nasonova S.N., Zhirov I.V., Khalilova U.A., Shirkin A.V., Shariya M.A., Tereshchenko S.N.

Abstract

Aim. To evaluate and compare the accuracy of volemic status determination by remote dielectric sensing with computed tomography (CT) in patients with acute decompensated heart failure.

Materials and methods. In 28 patients volemic status was determined by ReDS (remote dielectric sensing), chest computed tomography (CCT), and chest X-ray twice during hospitalization (the day of admission and the day of discharge from the hospital). The ReDS measurements were then compared with CT data using software that allows the use of semi-automated tools to determine mean lung density (MLD). MLD results from Hounsfield Units [HU] were then converted to fluid levels (FU%), allowing them to be compared with ReDS values. In addition, to assess the effect of physical activity on the dynamics of pulmonary stasis there was performed 6-minute walk test (6MWT) followed by determination of volumic status by ReDS method.

Results. Correlation analysis revealed an average direct significant correlation (r=+0,5; p=0.001) between the CCT and ReDS data. Hypervolemia indexes according to the CCT revealed statistically significant decrease in the dynamics, which was also reflected in the ReDS index decrease. Lung fluid content according to ReDS averaged 38.2±4.6% on admission, and 34.5±3.9% on discharge (p=0.005). According to CT scan of the CCT, MLD at admission was 23.03±3.9%, at discharge 19.6±3.3% (p=0.003). The positive dynamics of the study methods was also reflected in the positive dynamics of NT-proBNP, which decreased by 46%. In the analysis of ReDS data before and after exercise, there was an increase in ReDS value after the performed 6MWT and it was 35.09±3.9% compared with the initial value of 34.5±3.9%. A strong direct significant correlation (r=+0.7; p=0.0001) was found between the ReDS before and after 6MWT at discharge.

Terapevticheskii arkhiv. 2023;95(9):769-775
pages 769-775 views

A clinical and economic analysis of the use of dapagliflozin in patients with chronic heart failure in the entire spectrum of left ventricular ejection fraction in the Russian Federation

Nedogoda S.V., Tereshchenko S.N., Zhirov I.V., Salasyuk A.S., Barykina I.N., Lutova V.O., Popova E.A.

Abstract

Aim. To estimate the cost-effectiveness of dapagliflozin across the range of ejection fraction in patients with heart failure (HF) in Russian Federation.

Materials and methods. Cost-effectiveness model was developed for estimate the use of dapagliflozin as part of standard therapy in patients with HF regardless of ejection fraction is unknown. The calculation of costs was carried out in a mathematical model adapted to the conditions of Russian healthcare system by using Russian costs inputs and patient population characteristics.

Results. In the model, dapagliflozin therapy yielded a mean of 0.209 additional life-years compared with standard of care in 10 years horizon. The incremental cost of 1 additional life-year was 665,715 RUB, which does not exceed the threshold of willingness to pay 2,235,202 RUB.

Conclusion. Thus, the intensification of chronic HF therapy with dapagliflozin is cost effective. The use of dapagliflozin in a cohort of 1000 target patients over 10 years will avoid 146 hospitalizations and 39 emergency visits due to HF, as well as prevent 32 deaths from cardiovascular diseases.

Terapevticheskii arkhiv. 2023;95(9):782-788
pages 782-788 views

Effect of dapagliflozin on the dynamics of magnetic resonance imaging in patients with heart failure and atrial fibrillation

Saipudinova K.M., Uskach T.M., Shariya M.А., Ustyuzhanin D.V., Dobrovolskaya S.V., Tereshchenko S.N.

Abstract

Aim. To determine the effect of dapagliflozin therapy on myocardial remodeling and fibrosis according to magnetic resonance imaging (MRI) with contrast in patients with chronic heart failure (CHF) and atrial fibrillation (AF).

Materials and methods. In the group of 22 patients with a combination of CHF and AF we analyzed the dynamics of remodeling parameters and assessed myocardial fibrosis during 6-month therapy with dapagliflozin according to cardiac MRI with contrast.

Results.  After 6 months of dapagliflozin therapy there was a statistically significant increase in LVEF (27 [23-32]-32 [26.5-36.5] p-0.04) and a tendency to decrease volume and linear dimensions of LV, LP. There was no progression of myocardial fibrosis according to the results of cardiac MRI with contrast in patients with HFrFV and AF.

Conclusions. Dapagliflozin therapy in patients with HFrEF and AF led to favorable myocardial remodeling changes.

Terapevticheskii arkhiv. 2023;95(9):776-781
pages 776-781 views

Clinical notes

Difficulties in differential diagnosis of the AL- and ATTR-cardiac amyloidosis. Case report

Orlov F.I., Ansheles A.A., Nasonova S.N., Saidova M.A., Zhirov I.V., Stepanova E.A., Suvorina M.Y., Shoshina A.A., Tereshchenko S.N., Sergienko V.B.

Abstract

The article presents a clinical case describing a complex differential diagnosis of cardiac amyloidosis types and verification of the diagnosis of AL-amyloidosis.

Terapevticheskii arkhiv. 2023;95(9):789-795
pages 789-795 views

Reviews

The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist’s treatment: A review

Bobkova I.N.

Abstract

The renin-angiotensin-aldosterone system (RAAS) activation plays a key role in the chronic kidney disease (CKD) progression and in the cardiovascular complications (CVC) development in patients with diabetes mellitus (DM). RAAS blockers alone are not sufficient to prevent CVC and CVC progression. RAAS upregulation in CKD associated with DM triggers the mineralocorticoid receptors (MCR) hyperactivation which results in fibrosis and inflammation in the heart and kidneys. This review presents the current data about the variety of MCR hyperactivation manifestations, as well as about of multiplicity of MCR hyperactivation ways in DM. The efficacy and safety of finerenone, a new MCR nonsteroidal selective antagonist, are discussed.

Terapevticheskii arkhiv. 2023;95(9):796-801
pages 796-801 views

Sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: A review

Zhirov I.V., Safronova N.V., Tereshchenko S.N.

Abstract

Heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction are associated with significant morbidity and mortality, as well as growing economic burden. This review describes recent studies on the use of sacubitril/valsartan in heart failure patients with mildly reduced or preserved ejection fraction.

Terapevticheskii arkhiv. 2023;95(9):802-809
pages 802-809 views

Sartans in the treatment of arterial hypertension: focus on telmisartan and azilsartan. A review

Zakiev V.D., Kotovskaya Y.V., Tkacheva O.N.

Abstract

The activity of the renin-angiotensin-aldosterone system is one of the main pathogenetic mechanisms underlying cardiovascular diseases at all stages of the cardiovascular continuum. This article discusses the role of telmisartan and azilsartan as the most powerful sartans in modern cardiology. Azilsartan and especially telmisartan have a significant organoprotection and are superior to other antihypertensive drugs in terms of lowering blood pressure. However, the effect of azilsartan on hard endpoints has not been studied while the efficacy of telmisartan on hard endpoints has been evaluated in plenty clinical trials including 3 large randomized clinical trials with several thousand patients. The article also presents calculations showing the better cost-effectiveness of telmisartan compared to azilsartan.

Terapevticheskii arkhiv. 2023;95(9):810-817
pages 810-817 views

History of medicine

Computed tomography in cardiology: history and perspectives

Mironova O.I., Isaev G.O., Berdysheva M.V., Fomin V.V.

Abstract

The review article highlights the main stages of the formation of computed tomography (CT) as a key method used in modern cardiology. The progress of CT scanners is directly related to the increase in the number of detectors, and thus, with an increase in the number of simultaneously collected projections. Modern developments and future technologies in the field of further development of the technique, including CT angiography and other new methods for assessing coronary blood flow, are discussed. The use of artificial intelligence technologies may make it possible to improve and accelerate the interpretation of the resulting images in the future, especially if it is economically justified.

Terapevticheskii arkhiv. 2023;95(9):818-821
pages 818-821 views

Development of clinical medicine in Russia at the turn of the XIX–XX centuries: choice of the path. Once again about the founders of scientific internal medicine. Sergey Botkin and Grigory Zakharyin

Borodulin V.I., Banzelyuk E.N.

Abstract

On the basis of a critical analysis of numerous literary and archival sources, the authors confirm the idea of the decisive role of the Botkin’s direction in the development of the European science-based internal medicine in Russia and revise the canonical position about the three founders of this medicine: according to the authors, the founders of the scientific internal medicine in Russia were Sergey Botkin (Petersburg), Grigory Zakharyin, Alexey Ostroumov (Moscow) and Vassily Obraztsov (Kyiv). The topic is covered in two articles; this article is devoted to S. Botkin and G. Zakharyin.

Terapevticheskii arkhiv. 2023;95(9):822-826
pages 822-826 views

Anniversary of RAS Academician Evgeniy Lvovich Nasonov

Terapevticheskii arkhiv. 2023;95(9):827-828
pages 827-828 views


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies